CINJ Medical - Heme Malig

Medicine & Life Sciences

1. dinaciclib 100%
2. Hodgkin Disease 67%
3. Cyclin-Dependent Kinases 53%
4. Lymphoma 43%
5. Survival 31%
6. Progression-Free Survival 31%
7. Therapeutics 28%
8. Burkitt Lymphoma 28%
9. Non-Small Cell Lung Carcinoma 26%
10. T-Cell Lymphoma 25%
11. Neoplasms 21%
12. Hereditary Hemorrhagic Telangiectasia 21%
13. Brentuximab Vedotin 20%
14. Lymphoma, Large B-Cell, Diffuse 17%
15. Drug Therapy 16%
16. Non-Hodgkin's Lymphoma 16%
17. Apoptosis 16%
18. B-Cell Chronic Lymphocytic Leukemia 15%
19. Immunotherapy 15%
20. abexinostat 15%
21. DNA Sequence Analysis 15%
22. Hematopoietic Stem Cells 14%
23. belinostat 13%
24. Canidae 13%
25. ixazomib 13%
26. Pharmacokinetics 12%
27. MK 2206 12%
28. Cyclin-Dependent Kinase 2 12%
29. Chimeric Antigen Receptors 12%
30. Clinical Studies 12%
31. andrographolide 11%
32. Andrographis 11%
33. Hematopoietic Stem Cell Transplantation 11%
34. Aprepitant 11%
35. PCI 32765 11%
36. Mobile Health Units 10%
37. Transplants 10%
38. Cyclonic Storms 10%
39. Bispecific Antibodies 10%
40. Ipilimumab 10%
41. Nivolumab 10%
42. Cell- and Tissue-Based Therapy 10%
43. Diterpenes 10%
44. Tumor Burden 9%
45. Bevacizumab 9%
46. Rituximab 9%
47. Lactones 9%
48. Erlotinib Hydrochloride 9%
49. Glutens 9%
50. Clinical Trials 9%
51. Community Health Services 9%
52. Cell Line 9%
53. Bortezomib 9%
54. Malignant Mesothelioma 9%
55. Transitional Cell Carcinoma 8%
56. Heterografts 8%
57. Insurance Coverage 8%
58. Caspases 8%
59. Stem Cell Transplantation 8%
60. Radiotherapy 8%
61. Geriatrics 8%
62. Safety 8%
63. Homologous Transplantation 8%
64. Precursor Cell Lymphoblastic Leukemia-Lymphoma 8%
65. Cone-Beam Computed Tomography 8%
66. Radiosurgery 8%
67. Mutation 8%
68. Organ Transplantation 8%
69. Transplantation 8%
70. Graft vs Host Disease 7%
71. Reactive Oxygen Species 7%
72. Leukemia 7%
73. Central Nervous System 7%
74. Tumor Lysis Syndrome 7%
75. Vaccination 7%
76. Names 7%
77. Pancreatic Neoplasms 7%
78. Natural Killer Cells 6%
79. Human Influenza 6%
80. Survival Rate 6%
81. Standard of Care 6%
82. Multicenter Studies 6%
83. Hemorrhage 6%
84. Bleomycin 6%
85. Geriatric Assessment 6%
86. T-Lymphocytes 6%
87. Multivariate Analysis 6%
88. Urinary Bladder 5%
89. Lung Neoplasms 5%
90. Doxorubicin 5%
91. Acute Coronary Syndrome 5%
92. Kinetics 5%
93. Dacarbazine 5%
94. Activities of Daily Living 5%
95. Cohort Studies 5%
96. Heart Failure 5%